Welcome to our dedicated page for Lyra Therapeutics SEC filings (Ticker: LYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech can feel as complex as its science. Lyra Therapeutics’ SEC disclosures weave together XTREO platform chemistry, clinical trial milestones, and funding needs—information scattered across 200-page 10-K reports and surprise 8-K material event notices. Locating the right data points before the market reacts is a genuine challenge.
Stock Titan solves it. Our AI parses every Lyra Therapeutics quarterly earnings report 10-Q filing, extracts CRS pipeline costs, and charts cash runway in seconds. You’ll receive Lyra Therapeutics Form 4 insider transactions real-time, so shifts in executive stock transactions never slip past you. Plain-English overviews sit on top of every document, allowing understanding Lyra Therapeutics SEC documents with AI instead of wading through technical jargon.
Ask naturally—“How to read Lyra Therapeutics annual report 10-K simplified” or “Show me Lyra Therapeutics proxy statement executive compensation”—and the platform delivers direct answers plus the source filing. Alongside AI-powered highlights you’ll find:
- Lyra Therapeutics insider trading Form 4 transactions with drill-downs by officer
- Side-by-side Lyra Therapeutics earnings report filing analysis across quarters
- Instant alerts for Lyra Therapeutics 8-K material events explained in plain language
- Downloadable sections for due-diligence models
Whether you monitor dilution risk before a capital raise or verify CRS study endpoints, every Lyra Therapeutics SEC filing is updated the moment EDGAR posts. Complex biotech narratives, simplified: that’s our promise.
Lyra Therapeutics (NASDAQ:LYRA) filed an 8-K on June 26, 2025 disclosing a registered direct offering and concurrent private placement.
The company sold 273,012 common shares, 150,360 pre-funded warrants (exercise $0.001) and 846,744 private warrants (exercise $11.56) at a combined price of $11.81, generating about $4.3 million in net proceeds.
- H.C. Wainwright earns a 7 % placement fee plus 6.5 % on any future warrant cash exercise.
- Private warrants are immediately exercisable, expire 24 months after the resale registration statement is declared effective and include Black-Scholes cash-out rights upon a fundamental transaction.
- Beneficial-ownership caps: 9.99 % for pre-funded warrants, 4.99 % (optionally 9.99 %) for private warrants.
- Proceeds will fund working capital and further clinical, manufacturing and pre-commercial activities for LYR-210.
No additional material events were reported.
Lyra Therapeutics has announced a combined offering of 273,012 shares of common stock and pre-funded warrants to purchase 150,360 shares. The offering includes:
- Common stock priced at $11.81 per share with two accompanying private warrants
- Pre-funded warrants at $11.809 per underlying share with $0.001 exercise price
- Private warrants to purchase up to 846,744 shares at $11.56 exercise price
The total offering is expected to raise approximately $5 million before expenses, with $350,001 in placement agent fees. H.C. Wainwright & Co. is acting as exclusive placement agent. The company recently announced positive Phase 3 ENLIGHTEN 2 trial results for LYR-210 in chronic rhinosinusitis patients, meeting its primary endpoint with statistically significant improvement in cardinal symptoms at week 24.
The offering is subject to Form S-3 limitations, with aggregate market value of common stock held by non-affiliates at $29.2 million. Post-offering shares outstanding will be approximately 1.74 million, assuming full exercise of pre-funded warrants.
Lyra Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)). The company received written confirmation from Nasdaq on June 13, 2025 that its common stock maintained a bid price above $1.00 for 12 consecutive business days from May 28, 2025 to June 12, 2025.
Key details:
- Trading Symbol: LYRA on Nasdaq Capital Market
- Stock Type: Common Stock ($0.001 par value per share)
- Company Status: Emerging growth company
- Compliance Issue: Now resolved and closed
This development removes a significant regulatory concern for the company and ensures continued listing on the Nasdaq Capital Market. The filing was signed by CFO Jason Cavalier on June 23, 2025.
FAQ
What is the current stock price of Lyra Therapeutics (LYRA)?
What is the market cap of Lyra Therapeutics (LYRA)?
What is the primary focus of Lyra Therapeutics, Inc.?
How does the XTREO technology platform work?
What makes Lyra Therapeutics' product candidates unique?
In which market segments does the company operate?
How does Lyra Therapeutics differentiate itself from competitors?
What are the key components of the company’s clinical development program?
How is the company addressing patient needs in chronic rhinosinusitis?
